Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials

BACKGROUND: To assess the efficacy profile of erlotinib-based doublet targeted therapy compared with erlotinib monotherapy for previously treated patients with advanced NSCLC, a meta-analysis was performed. PATIENTS AND METHODS: We rigorously searched PubMed, Embase, Cochrane and meeting proceedings...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jian-Wei, Zhan, Ping, Qiu, Xiang-Yu, Jin, Jia-Jia, Lv, Tang-Feng, Song, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641210/
https://www.ncbi.nlm.nih.gov/pubmed/29069867
http://dx.doi.org/10.18632/oncotarget.18319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641210/
https://www.ncbi.nlm.nih.gov/pubmed/29069867
http://dx.doi.org/10.18632/oncotarget.18319

Ejemplares similares